

**Date: 13<sup>th</sup> November, 2024**

To,  
Department of Corporate Services,  
BSE Limited  
P. J. Towers,  
Dalal Street,  
Mumbai-400 001

**Scrip Code: 524604**

Dear Sir/Madam,

**Sub.: Outcome of Board of Directors Meeting of Adline Chem Lab Limited("the Company")**

Dear Sir/ Madam,

Pursuant to Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we wish to inform you that the Board of Directors of the Company at its meeting held today i.e., Wednesday, November 13<sup>th</sup>, 2024 at Registered Office of the Company has inter alia discussed following Agendas:

- (1) Considered and approved the Unaudited Financial Results along with Limited Review Report of the Company for the Quarter ended September 30<sup>th</sup>, 2024 (**Enclosed herewith**);
- (2) Appointment of Mr. Chintan Umeshbhai Bhatt (**DIN: 09289074**) as Additional Non-Executive Independent Director:

Pursuant to Regulation 30 of Listing Regulations, this is to inform you that on the recommendation of Nomination and Remuneration Committee, the Board of Directors of the Company in its meeting held on 13<sup>th</sup> November, 2024 has appointed Mr. Chintan Umeshbhai Bhatt (DIN: 09289074) as an Additional Director (Non-Executive, Independent) on the Board of the Company with effect from 13<sup>th</sup> November, 2024 pursuant to Section 149, 150, 152 read with Schedule IV and Section 161(1) read with the Companies (Appointment and Qualification of Directors) Rules, 2014 and other applicable provisions thereof, subject to the approval of shareholders at the General Meeting of the Company or within a time period of three months from the date of appointment, whichever is earlier.

Further, pursuant to the disclosure as required under Regulation 30 of the SEBI Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015, details of Mr. Chintan Umeshbhai Bhatt are enclosed as **Annexure-II**.

- (3) Reconstitution of Committees:

The Board in their meeting held today also considered Reconstitution of Audit Committee, Nomination & Remuneration Committee, Stakeholders Relationship Committee, and Independent Directors Committee, the details of which is annexed as **Annexure- III**.

CIN : L24231GJ1988PLC010956

**ADLINE CHEM LAB LIMITED** (Formerly Kamron Laboratories Limited)

Registered Office : 403, Sarthik II, Opp. Rajpath Club, S. G. Highway, Bodakdev, Ahmedabad - 380 054, Gujarat, INDIA.

Phone: 079 2687 0954 | E-mail : secretarial.adlinechemlab@gmail.com | Website: www.kamronlabs.com

The meeting of Board of Directors of the Company commenced at 03:00 P.M. and concluded at 06:30 P.M.

You are requested to kindly take the same on record and acknowledge.

**Yours faithfully,**

Thanking You,

**For, Adline Chem Lab Limited**

---

**Ritu Singh**  
**Company Secretary & Compliance Officer**  
**Membership No.: A24934**

**Encl: as above**

**The Board of Directors****ADLINE CHEMLAB LIMITED****Independent Limited Review Report on the quarterly unaudited Standalone Financial Results of the Company pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

1. We have reviewed the accompanying statement of unaudited financial results of Adline Chem Lab Ltd. (the "Company") for the quarter ended September 30, 2024 which include financial results ended on that date together with the relevant notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (The "Listing Regulations, 2015"). The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. This Statement, which is the responsibility of the Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.





4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with applicable Indian Accounting Standard ('Ind AS') and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Jain Kedia & Sharma  
Chartered Accountants  
FRN: 103920W**



*Tarak*  
**Tarak Shah  
Partner**

**Place: Ahmedabad**

**Date: November 13, 2024**

**Membership No. 182100  
UDIN: 24182100BKATFL1025**

**STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th September, 2024**

Particulars	(Rs in Lakhs)					
	Quarter Ended			Half Year Ended		Year Ended
	30th Sep 2024	30th June 2024	30th Sep 2023	30th Sep 2024	30th Sep 2023	31st Mar 2024
	Unaudited	Restated	Restated	Unaudited	Restated	Restated
Revenue from operations	-	-	-	-	-	-
Other income	-	-	0.01	-	0.01	0.01
<b>Total Income</b>	-	-	0.01	-	0.01	0.01
<b>Expenses</b>						
Cost of materials consumed	-	-	-	-	-	-
Purchase of Stock In Trade	-	-	-	-	-	-
Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	-	-	-	-	-	-
Employee benefits expense	4.71	3.61	0.90	8.33	2.59	4.36
Finance costs	3.39	3.31	3.07	6.70	6.07	12.44
Depreciation and amortization expense	-	-	-	-	-	-
Other expenses	2.02	6.55	2.31	8.57	8.80	13.49
<b>Total expenses</b>	<b>10.13</b>	<b>13.47</b>	<b>6.28</b>	<b>23.60</b>	<b>17.46</b>	<b>30.29</b>
<b>Profit/(loss) before exceptional items and tax</b>	<b>(10.13)</b>	<b>(13.47)</b>	<b>(6.27)</b>	<b>(23.60)</b>	<b>(17.44)</b>	<b>(30.28)</b>
Exceptional Items	-	-	-	-	-	-
<b>Profit/(loss) before tax</b>	<b>(10.13)</b>	<b>(13.47)</b>	<b>(6.27)</b>	<b>(23.60)</b>	<b>(17.44)</b>	<b>(30.28)</b>
<b>Tax expense:</b>	<b>(0.86)</b>	<b>(0.84)</b>	<b>(0.77)</b>	<b>(1.70)</b>	<b>(1.53)</b>	<b>(3.10)</b>
Current tax	-	-	-	-	-	-
Prior period tax	-	-	-	-	-	0.07
Deferred tax	(0.86)	(0.84)	(0.77)	(1.70)	(1.53)	(3.16)
<b>Profit (Loss) for the period from continuing operations</b>	<b>(9.27)</b>	<b>(12.63)</b>	<b>(5.49)</b>	<b>(21.90)</b>	<b>(15.92)</b>	<b>(27.18)</b>
Profit/(loss) from discontinued operations	-	-	-	-	-	-
Tax expense of discontinued operations	-	-	-	-	-	-
Profit/(loss) from Discontinued operations (after tax)	-	-	-	-	-	-
<b>Profit/(loss) for the period</b>	<b>(9.27)</b>	<b>(12.63)</b>	<b>(5.49)</b>	<b>(21.90)</b>	<b>(15.92)</b>	<b>(27.18)</b>
Other Comprehensive Income	0.46	0.46	-	0.92	-	0.05
Items that will not be reclassified to profit or loss (Net off tax)	0.46	0.46	-	0.92	-	0.05
Benefit due to actuarial valuation of gratuity	0.61	0.61	-	1.22	-	0.06
Deferred tax	(0.15)	(0.15)	-	(0.31)	-	(0.02)
Items that will be reclassified to profit or loss (Net of tax)	-	-	-	-	-	-
<b>Total Comprehensive Income for the</b>	<b>(8.81)</b>	<b>(12.17)</b>	<b>(5.49)</b>	<b>(20.98)</b>	<b>(15.92)</b>	<b>(27.13)</b>
Paid-up equity share capital (Face Value of the Share Rs. 10/- each)	585.00	585.00	585.00	585.00	585.00	585.00
<b>Earnings per equity share (for continuing operation):</b>						
Basic	(0.02)	(0.02)	(0.01)	(0.04)	(0.03)	(0.05)
Diluted	(0.02)	(0.02)	(0.01)	(0.04)	(0.03)	(0.05)
<b>Earnings per equity share (for discontinued operation):</b>						
Basic	(0.02)	(0.02)	(0.01)	(0.04)	(0.03)	(0.05)
Diluted	(0.02)	(0.02)	(0.01)	(0.04)	(0.03)	(0.05)
<b>Earnings per equity share (for continuing &amp; discontinued operation):</b>						
Basic	(0.02)	(0.02)	(0.01)	(0.04)	(0.03)	(0.05)
Diluted	(0.02)	(0.02)	(0.01)	(0.04)	(0.03)	(0.05)

**Notes:**

- This statement has been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 Accounting Standards Rules, 2015 (as amended). The statutory auditors of the company have carried out limited review of the financial results for the quarter ended September 30, 2024.
- These results have been reviewed and recommended for adoption by the Audit Committee in its meeting held on November 13, 2024, and approved by the Board of Directors at its meeting held on November 13, 2024. The Statutory Auditors Report does not have any qualification / modification.
- EPS is not annualized for the quarter ended September 30, 2024, June 30, 2024 and September 30, 2023 and for the half year ended September 30, 2024 and September 30, 2023.





**Reconciliation of restated results as required by Para 42 of Ind AS-8 "Accounting Policies, Changes in Accounting Estimates and Errors"**

Particulars	(Rs. in Lakhs)			
	Period ended 30/06/2024	Period ended 30/09/2023	Period ended 30/09/2023	Year ended 31/03/2024
Profit after tax as per published data	(10.13)	(3.20)	(11.38)	(14.66)
<b>Add / Less Adjustment due to restatements</b>				
Finance charge on Long Term Borrowings	(3.31)	(3.07)	(6.07)	(12.44)
Adjustment to the carrying value of Gratuity	(0.03)	-	-	(0.13)
Reversal of Gratuity written off as other income	-	-	-	(3.11)
<b>Total Adjustments due to restatements</b>	<b>(13.47)</b>	<b>(6.27)</b>	<b>(17.44)</b>	<b>(30.34)</b>
Deferred Tax on above Restatements	0.84	0.77	1.53	3.16
<b>Net profit before OCI [Restated]</b>	<b>(12.63)</b>	<b>(5.49)</b>	<b>(15.92)</b>	<b>(27.18)</b>
Adjustment to the carrying value of Gratuity	0.61	-	-	0.06
Deferred Tax on above Restatements	(0.15)	-	-	(0.02)
<b>Total Comprehensive Income [Restated]</b>	<b>(12.17)</b>	<b>(5.49)</b>	<b>(15.92)</b>	<b>(27.13)</b>

**Reconciliation of restated Other Equity between as required by Para 42 of Ind AS-8 "Accounting Policies, Changes in Accounting Estimates and Errors":**

Particulars	(Rs. in Lakhs)	
	As at 31st March 2024	As on 01st April 2023
<b>Equity as per published data</b>		
-Share Capital	585.00	585.00
-Other Equity	(756.41)	(741.75)
<b>Total Equity as per published data</b>	<b>(171.41)</b>	<b>(156.75)</b>
<b>Add / Less Adjustments due to restatements</b>		
Fair Valuation of Borrowings	24.89	24.89
Adjustment to the carrying value of Gratuity	27.71	27.71
Finance charge on Long Term Borrowings	(12.44)	-
Creation of Gratuity Provision out of P&L	(0.13)	-
Reversal of Gratuity written off as other income	(3.11)	-
Remeasurement benefits on Valuation of Gratuity	0.05	-
Deferred Tax on above restatements	(2.75)	(5.92)
<b>Total Equity ( Restated )</b>	<b>(137.20)</b>	<b>(110.07)</b>

Place: Ahmedabad  
Date: November 13, 2024



For, ADLINE CHEMLAB LIMITED

*[Signature]*

SARANG BHARATBHAI PATHAK  
MANAGING DIRECTOR  
DIN:02663344

**STANDALONE UNAUDITED STATEMENT OF ASSETS & LIABILITIES AS AT  
SEPTEMBER 30, 2024**

Particulars	(Rs in Lakhs)	
	As at 30th September 2024	As at 31st March 2024
<b>ASSETS</b>		
<b>Non-current assets</b>		
(a) Property, Plant and Equipment	-	-
(b) Capital work-in-progress	-	-
(c) Investment Property	-	-
(d) Goodwill	-	-
(e) Other Intangible assets	-	-
(f) Intangible assets under development	-	-
(g) Biological Assets other than bearer plants	-	-
(h) Financial Assets	-	-
(i) Investments	-	-
(ii) Trade receivables	-	-
(iii) Loans	-	-
(iv) Others (to be specified)	-	-
(i) Deferred Tax Assets	-	-
(j) Other non current assets	-	-
<b>Current assets</b>		
(a) Inventories	-	-
(b) Financial Assets	-	-
(i) Investments	-	-
(ii) Trade Receivable	-	-
(iii) Cash and cash equivalents	4.48	4.22
(iv) Bank balances other than (iii) above	-	-
(v) Loans	-	-
(vi) Others (to be specified)	-	-
(c) Current Tax Assets (Net)	-	-
(d) Other current assets	-	-
<b>TOTAL ASSETS</b>	<b>4.48</b>	<b>4.22</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity Share capital	585.00	585.00
(b) Other Equity	(743.18)	(722.20)
<b>Non-current liabilities</b>		
(a) Financial Liabilities	-	-
(i) Borrowings	-	-
(ia) Lease Liabilities	-	-
(ii) Trade payables	-	-
(iii) Other financial liabilities	-	-
(b) Provisions	0.29	0.33
(c) Deferred tax liabilities (Net)	1.37	2.77
(d) Other non-current liabilities	-	-
<b>Current liabilities</b>		
(a) Financial Liabilities	-	-
(i) Borrowings	158.76	135.84
(ia) Lease Liability	-	-
(ii) Trade payables	-	-
(iii) Other financial liabilities [other than those specified in item (c)]	-	-
(b) Other current liabilities	2.23	1.36
(c) Provisions	0.00	1.12
(d) Current Tax Liabilities (Net)	-	-
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>4.48</b>	<b>4.22</b>



**ADLINE CHEMLAB LIMITED**

Standalone statement of Cash flow for the Half year ended September 30,2024

Particulars	For the Half Year ended September 30,2024	For the Half Year ended September 30,2023
<b>Cash flow from operating activities</b>		
<b>1. Profit before tax</b>	(23.60)	(17.44)
	<b>(23.60)</b>	<b>(17.44)</b>
<b>2. Adjustment for :</b>		
Depreciation and amortisation expense	-	-
Finance cost	6.70	6.07
Interest income	-	(0.01)
Provision for Gratuity	0.07	-
Remasurement Benefit due to gratuity	1.22	-
<b>Operating profit before working capital changes (1+2)</b>	<b>(15.61)</b>	<b>(11.39)</b>
<b>3. Adjustments for working capital changes:</b>		
Decrease / (Increase) in Trade and other receivables	-	-
(Decrease) / Increase in Trade and other payables	-	-
Decrease / (Increase) in Inventory	-	-
( Increase) / (Decrease) in other current liabilities	0.87	1.66
( Increase) / (Decrease) in provisions	(1.23)	(0.05)
<b>Cash used in operations</b>	<b>(15.96)</b>	<b>(9.78)</b>
<b>Extraordinary item</b>		
<b>4. Direct taxes paid</b>		
Current tax	-	-
Prior Year's Adjustment	-	-
<b>Net Cash generated from/(used in) operating activities [A]</b>	<b>(15.96)</b>	<b>(9.78)</b>
<b>Cash Flow from investing activities</b>		
Purchase of fixed assets (including capital advances) (Net of CWIP trf)	-	-
Proceeds from sale of fixed assets	-	-
Share income (loss) from partnership firm	-	-
(Purchase) / Proceeds of non-current investments (Net)	-	-
Proceeds from Loans and Advances (Net)	-	-
Interest received	-	0.01
<b>Net cash generated from/(used in) investing activities [B]</b>	<b>-</b>	<b>0.01</b>
<b>Cash flow from financing activities</b>		
Proceeds from long term borrowings, net	-	13.82
Proceeds from short term borrowings, net	22.92	-
Finance cost	(6.70)	(6.07)
<b>Net cash generated from/(used in) financing activities [C]</b>	<b>16.22</b>	<b>7.76</b>
<b>Net increase/(decrease) in cash &amp; cash equivalents [A+B+C]</b>	<b>0.26</b>	<b>(2.01)</b>
Cash & cash equivalents at the beginning of the year	4.22	6.17
Cash & cash equivalents at the end of the year	4.48	4.16
<b>Cash &amp; cash equivalents</b>	<b>4.48</b>	<b>4.16</b>

The above cashflow statement has been prepared under the 'indirect method' as set out in the Indian Accounting Standard - 7 "Statement of Cash Flows".

The previous year's figures have been regrouped wherever necessary.

Place: Ahmedabad  
Date: November 13, 2024



For, ADLINE CHEMLAB LIMITED

SARANG BHARATBHAI PATHAK  
MANAGING DIRECTOR  
DIN:02663344



**Annexure- II**

Information as required under Regulation 30- Part A of Para A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

**Appointment of Mr. Chintan Umeshbhai Bhatt (DIN: 09289074) as Additional Non-Executive Independent Director**

S. No.	Particulars	Information of event
1.	Name of Non-Executive Independent Director	Mr. Chintan Umeshbhai Bhatt
1.	Reason for change viz. appointment, resignation, removal, death or otherwise	To increase the Transparency and Independency on Board. The Board of Directors on recommendation of Nomination and Remuneration Committee has appointed Mr. Chintan Umeshbhai Bhatt as an Additional Non-Executive Independent Director.
2.	Date of appointment & term of appointment	<b>Date of appointment:</b> Board, in its meeting held on November 13 <sup>th</sup> , 2024 has appointed Mr. Chintan Umeshbhai Bhatt as Non-Executive Independent Director of the Company w.e.f. from November 13 <sup>th</sup> , 2024 subject to the approval of shareholders. <b>Term of appointment:</b> Five years i.e. w.e.f. from November 13 <sup>th</sup> , 2024 to November 12 <sup>th</sup> 2029, subject to the approval of shareholders.
3.	Brief Profile	An Associate member of the Institute of Company Secretaries of India. Other Qualifications are Bachelor of Law (LL.B.), Commerce graduate (B. Com.), Diploma in Tax Practice (DTP) and Diploma in Labour Practice (DLP) awarded by Gujarat University. He has more than 5 Years of Experience in the field of Corporate law and Advisory services. He has expertise in Foreign Exchange Management Regulations, Compliances of Foreign Direct Investment and Overseas Investment.
4.	Disclosure of relationship between directors	Mr. Chintan Bhatt is not related to any other Director of the Company
5.	Affirmation that Director is not debarred from the holding office of director by virtue of any SEBI order or authority	Ms. Chintan Bhatt is not debarred from the holding the office of director by virtue of any SEBI order or any other such authority.

CIN : L24231GJ1988PLC010956

**ADLINE CHEM LAB LIMITED** (Formerly Kamron Laboratories Limited)

Registered Office : 403, Sarthik II, Opp. Rajpath Club, S. G. Highway, Bodakdev, Ahmedabad - 380 054, Gujarat, INDIA.

Phone: 079 2687 0954 | E-mail : secretarial.adlinechemlab@gmail.com | Website: www.kamronlabs.com

**Annexure-III**

**1) Reconstitution of Audit Committee as following members with effect from 13/11/2024:**

Sr. No.	Name	Committee Position	Company Designation
1	Mr. Chintan Umeshbhai Bhatt	Chairperson	Independent Director
2	Mr. Hemant A. Parikh	Member	Non-Executive Non-Independent Director
3	Ms. Shivani Pathak	Member	Independent Director

**2) Reconstitution of Nomination & Remuneration Committee as following members with effect from 13/11/2024:**

Sr. No.	Name	Committee Position	Company Designation
1	Ms. Shivani Pathak	Chairperson	Independent Director
2	Mr. Hemant A. Parikh	Member	Non-Executive Non-Independent Director
3	Mr. Chintan Umeshbhai Bhatt	Member	Independent Director

**3) Reconstitution of Stakeholders Relationship Committee as following members with effect from 13/11/2024:**

Sr. No.	Name	Committee Position	Company Designation
1	Mr. Chintan Umeshbhai Bhatt	Chairperson	Independent Director
2	Mr. Hemant A. Parikh	Member	Non-Executive, Non-Independent Director
3	Ms. Shivani Pathak	Member	Independent Director

**4) Reconstitution of Independent Director Committee as following members with effect from 13/11/2024:**

Sr. No.	Name	Committee Position	Company Designation
1	Ms. Shivani Pathak	Chairperson	Independent Director
2	Mr. Chintan Umeshbhai Bhatt	Member	Independent Director

CIN : L24231GJ1988PLC010956

**ADLINE CHEM LAB LIMITED** (Formerly Kamron Laboratories Limited)

Registered Office : 403, Sarthik II, Opp. Rajpath Club, S. G. Highway, Bodakdev, Ahmedabad - 380 054, Gujarat, INDIA.

Phone: 079 2687 0954 | E-mail : secretarial.adlinechemlab@gmail.com | Website: www.kamronlabs.com